Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Houston, Texas 77030


Objective is to assess the activity of the combination of thalidomide and dexamethasone in patients with previously untreated multiple myeloma.

Study summary:

This study will examine the potential efficacy of thalidomide-dexamethasone in the treatment of patients with previously untreated multiple myeloma. - Thalidomide is supplied as 50 mg capsules to be taken by mouth. - Thalidomide 200 mg daily each evening at bedtime increasing by 100-200 mg increments (according to patient tolerability) every 4 weeks. For elderly patients, or those with poor performance status or comorbid conditions which may affect tolerance of the thalidomide-dexamethasone combination, the initial dose may be reduced by 50-100 mg decrements and escalated weekly by 50-100 mg increments to tolerance. For patients who experience significant toxicity (> grade 2) or are otherwise unable to tolerate this drug combination, the dose will be reduced by 50-100 mg decrements. For some patients with > grade 2 toxicity, it may be necessary to hold the thalidomide dose until improvement of the side effect with subsequent resumption of the dose after dose reduction as outlined above. Dexamethasone 20mg/m2 each morning after breakfast on days 1-4, 9-12, 17-20, with a repeat cycle after a 1-2 week rest period. In case of partial remission, maintenance treatment with thalidomide alone will be continued for as long as remission is sustained at a dose free of side effects. For patients achieving CR, consolidation with thalidomide-dexamethasone for 4-6 months followed by follow-up without maintenance treatment. No maximum trial period is planned. At relapse patients may be reinitiated on the original thalidomide-pulse dexamethasone program and responding patients may be maintained on thalidomide alone (CR) or daily thalidomide and dexamethasone (days 1-4) until relapse. Patients who experience significant toxicity (grade 2 or more) at any time during therapy will receive a lower dose after treatment is interrupted. In an attempt to avoid deep venous thrombosis, all patients for whom anticoagulation is not contraindicated will be offered therapeutic anticoagulation (INR 1.5-2.5) with coumadin or therapeutic doses of low molecular weight heparin. Patients must be willing to return for evaluation every 4 weeks since thalidomide may only be prescribed for 28 day intervals.


- Previously untreated patients with symptomatic or progressive asymptomatic multiple myeloma. Criteria for progression among patients with asymptomatic disease include new lytic bone lesions, rise of serum myeloma protein to >5.0 gm/dl or fall of Hgb to <10.5 gm/dl. - Overt infection or unexplained fever should be resolved before treatment or treated concurrently with antibiotics. - Patients must provide written informed consent indicating that they are aware of the investigational nature of this study. - Patients with idiopathic monoclonal gammopathy or stable asymptomatic myeloma are ineligible. - Patients whose only prior therapy has been with local radiotherapy or alpha interferon are eligible. - Patients treated with steroids in order to stabilize disease within 60 days prior to enrollment are eligible. - Patients exposed to longer periods of high-dose glucocorticoid, or with any exposure to thalidomide or alkylating agent are ineligible.

Study is Available At:

Original ID:




Secondary ID:

Study Acronym:

Brief Title:

Thalidomide-Dexamethasone for Multiple Myeloma

Official Title:

Thalidomide-Dexamethasone for Multiple Myeloma

Overall Status:


Study Phase:

Phase 2/Phase 3



Minimum Age:


Maximum Age:


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

M.D. Anderson Cancer Center

Oversight Authority:

United States: Food and Drug Administration

Reasons Why Stopped:

Study Type:


Study Design:

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:Donna M Weber, M.D.
Study Chair
UT MD Anderson Cancer Center

Study Dates

Start Date:June 2000
Completion Date:May 2005
Completion Type:Actual
Primary Completion Date:May 2005
Primary Completion Type:Actual
Verification Date:October 2018
Last Changed Date:October 30, 2018
First Received Date:May 28, 2002

Study Outcomes

Outcome Type:Primary Outcome
Measure:Response Rate
Time Frame:Baseline, with each course and monthly tests
Safety Issues:False

Study Interventions

Intervention Type:Drug
Description:100 mg capsules by mouth daily each evening
Arm Name:Thalidomide + Dexamethasone
Other Name:Thalomid
Intervention Type:Drug
Description:20 mg/m^2 taken by mouth each morning on days 1-4, 9-12 and 17-20.
Arm Name:Thalidomide + Dexamethasone
Other Name:Decadron

Study Arms

Study Arm Type:Experimental
Arm Name:Thalidomide + Dexamethasone

Study Agencies

Agency Class:Other
Agency Type:Lead Sponsor
Agency Name:M.D. Anderson Cancer Center
Agency Class:Industry
Agency Type:Collaborator
Agency Name:Celgene Corporation

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.